Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

89.58 +0.17 (+0.20%)
Streaming Delayed Price Updated: 3:18 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
73 74 Next >
News headline image
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
News headline image
4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗
The growth-fueled Nasdaq Composite is 9% below its record high, meaning amazing deals are still hiding in plain sight. 
Via The Motley Fool
Topics Stocks
News headline image
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada ↗
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
News headline image
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry ↗
 
Via Benzinga
News headline image
Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies ↗
 
Via Benzinga
News headline image
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs ↗
Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price 
Via Benzinga
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024 ↗
These are the undervalued and fundamentally strong dividend-paying stocks to buy for high total returns in the next 24 to 36 months. 
Via InvestorPlace
News headline image
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today ↗
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. 
Via InvestorPlace
News headline image
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants ↗
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD 
Via Benzinga
News headline image
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... 
Via Talk Markets
News headline image
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer ↗
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. 
Via Benzinga
News headline image
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review ↗
The major indexes boast big annual gains with the Dow at record highs. 
Via Investor's Business Daily
Topics Stocks
News headline image
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024 ↗
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
News headline image
Why Is Blood Purification Focused CytoSorbents Trading Lower Today? ↗
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the... 
Via Benzinga
News headline image
The Decline In Global Bond Yields Supports Stock Indices ↗
A decline in global bond yields is lending support to stocks on optimism that global central banks will start cutting interest rates next year. 
Via Talk Markets
Topics Bonds
News headline image
Why Is Cytokinetics (CYTK) Stock Up 70% Today? ↗
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest. 
Via InvestorPlace
News headline image
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned ↗
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole... 
Via Benzinga
News headline image
Investor Sentiment Improves; Dow Jumps Over 150 Points ↗
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The... 
Via Benzinga
Topics Stocks
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Crude Oil Rises Over 3%; US Home Prices Increase In October ↗
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The... 
Via Benzinga
Topics Stocks
News headline image
US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs ↗
Stocks appear on track to start Tuesday's session on a positive note amid positive expectations concerning interest rates and economy. 
Via Benzinga
News headline image
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies ↗
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio. 
Via Benzinga
News headline image
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
From AstraZeneca
Via Business Wire
News headline image
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am 
Via Benzinga
News headline image
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗
Friday, FDA approved AstraZeneca 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.